Winnie Liu1, Roula Shraiky Zahr1, Shirley McCartney2,3, Justin S Cetas2,3, Aclan Dogan2,3, Maria Fleseriu4,5,6. 1. Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA. 2. Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. 3. Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA. 4. Department of Medicine, Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu. 5. Department of Neurological Surgery, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu. 6. Northwest Pituitary Center, Oregon Health & Science University, Portland, OR, USA. fleseriu@ohsu.edu.
Abstract
PURPOSE: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center's pre-operative evaluation, patient characteristics and outcomes of male LAs patients requiring pituitary surgery. METHODS: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAs patients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted. RESULTS: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75% vs. 44.7% p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6% vs. 42.1%, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9% vs. 24.1%, p = NS) and radiation therapy (18.4% vs. 19.4%, p = NS). CONCLUSIONS: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.
PURPOSE: Lactotroph adenomas (LA) are the most frequently encountered pituitary tumors. Although more frequently observed in women, LAs in men were recently included in a more aggressive category regardless of histological grading, by the WHO. We aimed to perform a rigorous retrospective review of a single center's pre-operative evaluation, patient characteristics and outcomes of male LAspatients requiring pituitary surgery. METHODS: A retrospective review, over 11 years, of patients who underwent resection of a pituitary adenoma at a single center was conducted. Predictors of persistent disease in male LAspatients along with a comparison to predictors of silent corticotroph adenomas (SCAs) patients who also underwent surgery at the center was also conducted. RESULTS: Thirty-one male patients with LAs were identified. When compared to SCAs patients, LAs male patients were younger (41 vs. 50 years of age, p = 0.01). Men with LAs had more invasive tumors (75% vs. 44.7% p = 0.02). More LAs in men had residual tumor after surgery than patients with SCA (92.6% vs. 42.1%, p < 0.001). Male patients with LAs and patients with SCA had similar rates of requiring additional surgery (28.9% vs. 24.1%, p = NS) and radiation therapy (18.4% vs. 19.4%, p = NS). CONCLUSIONS: High rates of DA resistance, invasive tumors and postoperative residual disease in male patients with LA who required surgery are shown. Surgery improved optic chiasm compression, PRL level and central hypogonadism but, not surprisingly, failed to normalize other pituitary hormones and/or eliminate need for DA therapy.
Authors: Michael E Sughrue; Edward F Chang; J Blake Tyrell; Sandeep Kunwar; Charles B Wilson; Lewis S Blevins Journal: Pituitary Date: 2009 Impact factor: 4.107
Authors: Bin Zhu; Ming Gao; Lei Zhang; Juan Wang; Lei Wang; Ling Ling Qin; Xi Xiong Kang; Zhi Gang Zhao Journal: Metab Brain Dis Date: 2019-01-03 Impact factor: 3.584
Authors: Odelia Cooper; Vivien S Bonert; Jeremy Rudnick; Barry D Pressman; Janet Lo; Roberto Salvatori; Kevin C J Yuen; Maria Fleseriu; Shlomo Melmed Journal: J Clin Endocrinol Metab Date: 2021-01-23 Impact factor: 5.958
Authors: José Miguel Hinojosa-Amaya; Nathaniel Johnson; Christina González-Torres; Elena V Varlamov; Christine G Yedinak; Shirley McCartney; Maria Fleseriu Journal: Front Endocrinol (Lausanne) Date: 2020-10-27 Impact factor: 5.555